If you had hernia surgery using Covidien mesh (Parietex, Symbotex, or ProGrip) and suffered complications, you may have a legal claim. MDL 3029 — No settlement yet. First trial set July 2026. Free case review.
Start Your Free Case Review →Hernia repair is one of the most common surgical procedures performed in the United States, with more than a million operations every year. In most of these surgeries, a synthetic mesh device is implanted to reinforce the abdominal wall and prevent the hernia from returning. Patients are typically told that the procedure is routine and that the mesh is safe for long-term use inside the body.
For thousands of people who received a Covidien hernia mesh product — including Parietex, Symbotex, and ProGrip — that assurance has proven devastatingly wrong. These patients have developed chronic pain that did not exist before surgery, had organs become fused to the mesh through scar tissue, required emergency procedures for bowel obstructions, and undergone multiple revision surgeries to address complications that their original surgeons never warned them were possible.
Lawsuits against Covidien — now a subsidiary of Medtronic — allege that its mesh products were defectively designed, that the company knew about the risks and concealed them, and that patients were implanted with devices that should never have been used in the human body without proper clinical testing. If you had hernia surgery using a Covidien mesh product and have suffered complications, you may have a legal claim.
The litigation centers on Covidien’s line of polyester and composite mesh devices. The specific products most commonly at issue include:
In 2018, Medtronic issued a voluntary recall of Parietex Composite Mesh after reports of mesh failure occurring years after implantation. That recall is central to many of the pending lawsuits.
If you are not certain which mesh product was used in your surgery, your operative report and surgical records will identify the specific device implanted. An attorney can help you obtain those records.
The lawsuits allege a constellation of design defects that are specific to Covidien’s polyester-based products:
Degradation and shrinkage. Plaintiffs allege that Covidien’s polyester mesh becomes brittle and shrinks significantly after implantation — in some cases contracting by 30 to 50 percent of its original size. As the mesh shrinks, it pulls on surrounding tissue, causing severe chronic pain and distortion of the abdominal wall.
Premature coating resorption in Symbotex. The Symbotex mesh was engineered with a collagen coating specifically designed to create a barrier between the mesh and internal organs, preventing adhesions. Plaintiffs allege that this coating resorbs — dissolves — far too quickly, leaving bare polyester mesh in direct contact with the bowels and other organs. The result is exactly the adhesion formation the coating was supposed to prevent, sometimes causing organ fusion and bowel obstruction severe enough to require emergency surgery.
Inflammatory reaction. The body’s immune system recognizes the polyester material as foreign and may mount a prolonged inflammatory response, leading to chronic pain, tissue damage, and infection that antibiotics cannot resolve.
FDA clearance without clinical trials. Discovery in the MDL has produced nearly 2 million Covidien documents. Plaintiffs allege that this evidence shows Covidien brought many of its mesh products to market using the FDA’s 510(k) pathway — a clearance process that does not require clinical trials, only a showing that the product is “substantially equivalent” to an already-marketed device — without adequately testing the long-term safety of its specific formulations in humans.
2,387 federal cases pending in MDL 3029. As of April 2026, there are 2,387 lawsuits against Covidien pending in the federal MDL before Judge Patti B. Saris in the District of Massachusetts. In addition, more than 6,000 cases are pending in Massachusetts state court, and additional cases are consolidated in Minnesota state court — making this a true multi-front litigation. Plaintiffs’ attorneys tracking both the Covidien and Bard dockets characterize the Covidien cases as factually stronger, with the polyester design defects and documentary evidence offering a compelling liability narrative.
First bellwether trial set for July 13, 2026. The first federal bellwether trial, Patterson v. Covidien — involving a Symbotex mesh that was implanted in an Alabama plaintiff and allegedly caused severe adhesions requiring small bowel resection — is currently scheduled to begin July 13, 2026, after it was previously postponed earlier this year. A second bellwether trial, Regina Stephen v. Covidien, involving a Mississippi plaintiff who allegedly suffered adhesions, bowel problems, chronic inflammation, and need for corrective surgery after a Symbotex implant, is also scheduled in 2026. A third bellwether pool includes Wardell v. Covidien and Baisden v. Covidien, both involving Parietex Composite mesh.
No global settlement — and the trial is the pressure point. Recent settlement negotiations did not yield a resolution, and no global settlement has been announced. Experienced mass tort attorneys view the July 2026 bellwether as the moment that will define the litigation’s trajectory — a plaintiff verdict is widely expected to accelerate settlement pressure on Covidien and its parent Medtronic, which has far deeper pockets than many other hernia mesh defendants.
Nearly 2 million documents produced. The discovery process has been extensive. In April 2025, Judge Saris ordered Covidien to disclose its marketing and promotional spending, signaling the court’s interest in the company’s corporate conduct beyond the product design itself. The volume of internal documents already produced gives plaintiffs’ teams a rich record to work with going into trial.
Why now matters. Attorneys experienced in mass tort litigation note that 2026 may be the last practical window for new plaintiffs to join and benefit from global settlement pressure before any resolution is finalized. Filing now positions a claim within the MDL structure and preserves the ability to participate in whatever settlement program ultimately emerges.
The strongest Covidien hernia mesh cases involve serious, documented complications that required medical intervention after the mesh implantation. These include:
You may have a Covidien hernia mesh claim if:
Surviving family members may be able to bring a claim on behalf of a loved one who died from complications related to a Covidien hernia mesh implant.
Hernia mesh litigation involves products made by several different manufacturers, including C.R. Bard (Davol), Ethicon (Johnson & Johnson), and Atrium Medical — each of which has its own separate MDL and litigation status. We are currently accepting Covidien cases only. If you had hernia surgery but are not certain which manufacturer’s mesh was used, please contact us — we can help you identify the product from your surgical records and advise on next steps.
Your operative report — part of your surgical record from the hospital or surgery center — will identify the specific mesh product implanted, including the manufacturer, product name, lot number, and size. You can request these records directly from your healthcare provider. If you had surgery at a hospital system, the medical records department can provide these documents, often within 30 days of a written request. Your attorney can also assist with this process.
This is one of the most common situations in hernia mesh litigation. Mesh degradation, shrinkage, and adhesion formation are progressive processes — complications often emerge or worsen over months and years. Most states apply a discovery rule that starts the statute of limitations clock from the date you knew or reasonably should have known that your complications were caused by the mesh, not simply from your surgery date. Do not assume time has run out without consulting an attorney.
No. Your surgeon’s opinion is one piece of evidence, not a legal determination. Causation in these cases is addressed through independent expert review of your records, imaging, and pathology. Many patients whose treating surgeons attributed their pain to other causes have gone on to have viable mesh claims established through expert analysis.
Yes — and mesh removal cases are often among the strongest. Removed mesh can be preserved and analyzed, sometimes revealing the degradation, bacterial colonization, or structural failure that plaintiffs allege. The removal surgery itself, and any procedures required to address complications from the removal, are part of your compensable damages.
Covidien was acquired by Medtronic in 2015. Medtronic is one of the world’s largest medical device companies and the ultimate corporate parent responsible for Covidien’s products and liabilities. The involvement of a financially substantial defendant is relevant to the potential for meaningful settlement compensation.
Get a free, no obligation case evaluation here.